Section one: Contracting authority
one.1) Name and addresses
NHS England
7-8 Wellington Place
Leeds
LS1 4AP
Contact
Stacey Thrower
Country
United Kingdom
Region code
UK - United Kingdom
Internet address(es)
Main address
Buyer's address
one.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at
https://health-family.force.com/s/Welcome
Additional information can be obtained from the above-mentioned address
Tenders or requests to participate must be submitted electronically via
https://health-family.force.com/s/Welcome
Tenders or requests to participate must be submitted to the above-mentioned address
Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at
https://health-family.force.com/s/Welcome
one.4) Type of the contracting authority
Body governed by public law
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Provision of Community Pharmacy Respiratory Syncytial Virus (RSV) Vaccination within the East of England Region
Reference number
AG24517
two.1.2) Main CPV code
- 85100000 - Health services
two.1.3) Type of contract
Services
two.1.4) Short description
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHE England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy Respiratory Syncytial Virus (RSV) Vaccination within the East of England Region
Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:
• an adult programme (predominately to be commissioned through general practice); and
• an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).
This Procurement Process is for the Early Adoption Phase in the East of England Region where up to 50 Potential Suppliers will be selected to provide the services. The 50 Successful Suppliers will be in 2 ICBs within the East of England Region to allow the Commissioner to ensure an even geographical spread. The ICB's included in this procurement are NHS Mid and South Essex ICB and Suffolk and North East Essex ICB.
The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV vaccine to each eligible patient.
The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner’s control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.
Services will commence in September 2024 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.
Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on 7th August 2024.
two.1.6) Information about lots
This contract is divided into lots: Yes
Tenders may be submitted for one lot only
two.2) Description
two.2.1) Title
Lot 1 - NHS Mid and South Essex ICB
Lot No
1
two.2.2) Additional CPV code(s)
- 85100000 - Health services
two.2.3) Place of performance
NUTS codes
- UKH - East of England
two.2.4) Description of the procurement
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHE England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy Respiratory Syncytial Virus (RSV) Vaccination within the East of England Region
Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:
• an adult programme (predominately to be commissioned through general practice); and
• an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).
This Procurement Process is for the Early Adoption Phase in the East of England Region where up to 50 Potential Suppliers will be selected to provide the services. The 50 Successful Suppliers will be in 2 ICBs within the East of England Region to allow the Commissioner to ensure an even geographical spread. The ICB's included in this procurement are NHS Mid and South Essex ICB and Suffolk and North East Essex ICB.
The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV vaccine to each eligible patient.
The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner’s control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.
Services will commence in September 2024 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.
The award criteria is as stated below:
Integration, collaboration and service sustainability - 40.00%
Improving access, reducing health inequalities and facilitating choice - 45.00%
Quality and Innovation - 5.00%
Social Value - 10.00%
Value - Pass / Fail
Please see published procurement documentation for further details. All relevant information on the stages of evaluation are stated within the ITT documentation suite.
Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on 7th August 2024.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
23 September 2024
End date
31 March 2029
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 2 - Suffolk and North East Essex ICB
Lot No
2
two.2.2) Additional CPV code(s)
- 85100000 - Health services
two.2.3) Place of performance
NUTS codes
- UKH - East of England
two.2.4) Description of the procurement
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHE England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy Respiratory Syncytial Virus (RSV) Vaccination within the East of England Region
Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:
• an adult programme (predominately to be commissioned through general practice); and
• an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).
This Procurement Process is for the Early Adoption Phase in the East of England Region where up to 50 Potential Suppliers will be selected to provide the services. The 50 Successful Suppliers will be in 2 ICBs within the East of England Region to allow the Commissioner to ensure an even geographical spread. The ICB's included in this procurement are NHS Mid and South Essex ICB and Suffolk and North East Essex ICB.
The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV vaccine to each eligible patient.
The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner’s control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.
Services will commence in September 2024 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.
The award criteria is as stated below:
Integration, collaboration and service sustainability - 40.00%
Improving access, reducing health inequalities and facilitating choice - 45.00%
Quality and Innovation - 5.00%
Social Value - 10.00%
Value - Pass / Fail
Please see published procurement documentation for further details. All relevant information on the stages of evaluation are stated within the ITT documentation suite.
Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on 7th August 2024.
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
3 September 2024
End date
31 March 2029
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
Section three. Legal, economic, financial and technical information
three.1) Conditions for participation
three.1.2) Economic and financial standing
Selection criteria as stated in the procurement documents
three.1.3) Technical and professional ability
Selection criteria as stated in the procurement documents
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Open procedure
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: No
four.2) Administrative information
four.2.2) Time limit for receipt of tenders or requests to participate
Date
7 August 2024
Local time
12:00pm
four.2.4) Languages in which tenders or requests to participate may be submitted
English
four.2.6) Minimum time frame during which the tenderer must maintain the tender
Duration in months: 6 (from the date stated for receipt of tender)
four.2.7) Conditions for opening of tenders
Date
22 July 2024
Local time
2:00pm
Section six. Complementary information
six.1) Information about recurrence
This is a recurrent procurement: No
six.3) Additional information
This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.
The Contracting Authority will be using an eTendering system for this procurement exercise.
Further information and the ITT documentation can be found via the 'Live Opportunities' list on the e-tendering system at the following link:
https://health-family-contract-search.secure.force.com/?searchtype=Projects
You can also register your interest via this page. You can search for the opportunity by entering the following contract reference: C297044 - COMPETITIVE: RSV Community Pharmacy Pathfinder Service
Neither the publication of this notice nor the employment of any particular terminology nor any other indication shall be taken to mean that the Contracting Authority intends to hold itself bound by any of the Regulations.
The award criteria is as stated below:
Integration, collaboration and service sustainability - 40.00%
Improving access, reducing health inequalities and facilitating choice - 45.00%
Quality and Innovation - 5.00%
Social Value - 10.00%
Value - Pass / Fail
Please see published procurement documentation for further details. All relevant information on the stages of evaluation are stated within the ITT documentation suite.
six.4) Procedures for review
six.4.1) Review body
NHS England
7-8 Wellington Place
Leeds
LS1 4AP
Country
United Kingdom
Internet address
six.4.2) Body responsible for mediation procedures
NHS Arden and GEM CSU
St John's House, East Street
Leicester
LE1 6NB
Country
United Kingdom
Internet address
https://www.ardengemcsu.nhs.uk/
six.4.4) Service from which information about the review procedure may be obtained
NHS Arden and GEM CSU
St John's House, East Street
Leicester
LE1 6NB
Country
United Kingdom